标题
Frequent adaptive immune responses against arginase-1
作者
关键词
-
出版物
OncoImmunology
Volume 7, Issue 3, Pages e1404215
出版商
Informa UK Limited
发表日期
2017-11-16
DOI
10.1080/2162402x.2017.1404215
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells
- (2017) Giada Mondanelli et al. IMMUNITY
- Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
- (2017) Franck Carbonnel et al. Seminars in Immunopathology
- T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells
- (2016) Ilaria Marigo et al. CANCER CELL
- Anti-regulatory T cells
- (2016) Mads Hald Andersen Seminars in Immunopathology
- Myeloid-derived suppressor cells and tumor escape from immune surveillance
- (2016) Viktor Umansky et al. Seminars in Immunopathology
- Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer
- (2016) Jinhoi Song et al. Oncotarget
- The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma
- (2016) Alessandra Romano et al. Oncotarget
- Immunosuppressive CD14+HLA-DRlo/neg monocytes are elevated in pancreatic cancer and “primed” by tumor-derived exosomes
- (2016) Naureen Javeed et al. OncoImmunology
- Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening
- (2016) Matthias Schröder et al. OncoImmunology
- Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy
- (2015) M. H. Andersen JNCI-Journal of the National Cancer Institute
- Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer
- (2015) Hiroshi Katoh et al. MEDIATORS OF INFLAMMATION
- Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy
- (2015) M. H. Andersen JNCI-Journal of the National Cancer Institute
- Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course
- (2015) An Coosemans et al. OncoImmunology
- Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells
- (2015) Svetlana Karakhanova et al. OncoImmunology
- The targeting of immunosuppressive mechanisms in hematological malignancies
- (2014) M H Andersen LEUKEMIA
- Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment
- (2013) F. Mussai et al. BLOOD
- HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients
- (2013) S. Munir et al. CANCER RESEARCH
- Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells
- (2013) S Munir et al. LEUKEMIA
- Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway
- (2013) S M Ahmad et al. LEUKEMIA
- The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+T cells
- (2013) Shamaila Munir et al. OncoImmunology
- High-Avidity T Cells Are Preferentially Tolerized in the Tumor Microenvironment
- (2012) Z. Zhu et al. CANCER RESEARCH
- Natural CD4+ T-Cell Responses against Indoleamine 2,3-Dioxygenase
- (2012) Shamaila Munir et al. PLoS One
- Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators
- (2010) R. B. Sorensen et al. BLOOD
- High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer
- (2010) Özcan Met et al. BREAST CANCER RESEARCH AND TREATMENT
- The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
- (2009) Rikke Bæk Sørensen et al. PLoS One
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started